NCT06547957View on ClinicalTrials.gov

A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 7, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Solid Tumors
Interventions
DRUG

EOS301984

Multiple doses of EOS301984

DRUG

Anti-PD-1 monoclonal antibody

Multiple doses of EOS301984 in combination with Anti-PD-1

Trial Locations (6)

1070

Institut Jules Bordet, Brussels

1200

Cliniques Universitaires Saint-Luc, Brussels

2610

GZA Ziekenhuizen campus Sint-Augustinus, Wilrijk

4000

CHU de Liège, Liège

6060

Grand Hopital de Charleroi, Charleroi

9000

Universitair Ziekenhuis Gent, Ghent

Sponsors

Lead Sponsor

iTeos Therapeutics
All Listed Sponsors
lead

iTeos Therapeutics

INDUSTRY

NCT06547957 - A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter